Tolerx

Tolerx is responsible for the clinical and regulatory activities for otelixizumab in Type 1 diabetes in the U.S. and has the option to jointly promote otelixizumab in Type 1 diabetes in the U.S. with Glaxo, while the U.K. drug maker has exclusive rights to develop and commercialize otelixizumab in all other indications in the rest of the world.

Glaxo's BTG Drug Fails to Pass Trial Sten Stovall 2011

*** Pharmaceuticals GlaxoSmithKline and U.S. partner Tolerx said their experimental drug otelixizumab failed to achieve its target in a late-stage clinical trial for Type 1 diabetes.

Business Watch 2011

LONDON— GlaxoSmithKline PLC and its U.S. partner Tolerx Inc. Friday said their experimental drug otelixizumab failed to pass a late-stage clinical trial for Type 1 diabetes.

Glaxo's BTG Drug Fails to Pass Trial Sten Stovall 2011

Glaxo and Tolerx set up an alliance in October 2007 to develop and commercialize otelixizumab for a range of autoimmune and immune-mediated inflammatory diseases, including Type 1 diabetes.

Glaxo's BTG Drug Fails to Pass Trial Sten Stovall 2011

Otelixizumab is being developed in collaboration with Glaxo and Tolerx.

Glaxo's BTG Drug Fails to Pass Trial Sten Stovall 2011

Tolerx will receive $70 million upfront and may earn as much as $350 million if development is successful.

Glaxo and Mylan Settle 2007

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

THE MEDICAL NEWS 2010

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

THE MEDICAL NEWS 2010

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

THE MEDICAL NEWS 2010

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

THE MEDICAL NEWS 2010